MedTrace Logo

Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression

NCT00159146 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2007-12-27

No results posted yet for this study

Summary

This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.

Conditions

Interventions

DRUG

Pindolol and venlafaxin

pindolol 20 mg and venlafaxin 150 mg

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Tvergaards Foundation

    collaborator UNKNOWN

  • Hillerod Hospital, Denmark

    lead OTHER

Principal Investigators

  • Per Bech, Professor · Psychiatric Research Unit, Hillerod Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Completion
2007-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00159146 on ClinicalTrials.gov